A Phase 1 interventional study of Roxadustat in Normal Renal Function and Impaired Renal Function, sponsored by Astellas Pharma Europe B.V.. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-02-12.
Sponsored by Astellas Pharma Europe B.V. (part of Astellas Pharma Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Renal Insufficiency by Astellas Pharma Inc — none open to participants now, none under way, none of them phase 3. Renal Insufficiency · Astellas Pharma Inc.
Among the 17 studies in Renal Insufficiency by Astellas Pharma Inc, this one is the 9th largest by enrollment of the 16 interventional ones that give a count, is the only one that started in 2016, is one of 9 in phase 1, and was the 14th registered.
1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.
Browse Renal Insufficiency studies →None of the 17 studies in Renal Insufficiency by Astellas Pharma Inc is open now. The open studies under Renal Insufficiency, anywhere →
Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 1 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 34 is below the median of 40 across 1,061 interventional studies indexed under Renal Insufficiency.
Median enrollment 35 across the 16 interventional studies, 1,484 across the 1 observational. Of the 17 that completed or were terminated, 1 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Astellas Pharma Europe B.V., one of the names counted as Astellas Pharma Inc. Under that name alone:
Astellas Pharma Europe B.V. is the lead sponsor of 94 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 17 studies in Renal Insufficiency by Astellas Pharma Inc, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
For subjects with normal renal function or severely impaired renal function, this study will evaluate the pharmacokinetics of roxadustat and its main metabolites in plasma and urine.
For subjects with end stage renal disease (ESRD) on continuous ambulatory peritoneal dialysis (CAPD) or automated peritoneal dialysis (APD), this study will evaluate the pharmacokinetics of roxadustat and its main metabolites in plasma, urine and dialysate.
For subjects with ESRD on hemodialysis (HD) or hemodiafiltration (HDF), this study will evaluate the pharmacokinetics of roxadustat and its main metabolites in plasma, urine and dialysate and also the effect of dialysis on the pharmacokinetics of roxadustat and its main metabolites.
This is a phase 1, open-label study in two sites. There will be four different renal function groups.
For all subjects:
Subjects will be allocated to the normal and severely impaired renal function groups based on estimated glomerular filtration rate (eGFR), calculated with the abbreviated modification of diet in renal disease (MDRD) equation. The eGFR will be based on the serum creatinine concentration and is assessed at screening and at day -2. The eGFR obtained at screening will determine the allocation.
Subjects will be allocated to the ESRD groups based on their dialysis requirements.
Subjects with normal and severely impaired renal function, and subjects with ESRD on CAPD or APD:
Screening will take place from day -30 to day -3 and the subjects will be admitted to the clinical unit on day -2. The treatment period lasts 8 days, during which the subjects will receive a single oral dose of roxadustat in the morning of day 1 Subjects will complete the treatment period on day 6, provided that all required assessments have been performed and there are no medical reasons for a prolonged follow-up. The study will be completed with an end-of-study visit (ESV), which will take place between 5 and 9 days after the last treatment period-defined assessment (or after early withdrawal).
Subjects with ESRD on HD or HDF:
Screening will take place from day -30 to day -3 and subjects will complete 2 treatment periods of 8 days (period 1) and 7 days (period 2) in order to evaluate the pharmacokinetics of roxadustat with a single oral dose of roxadustat on day 1 of both periods after and before dialysis.
Subjects will complete the treatment period 1 on day 6 followed by a wash-out period which is minimally 1 week and maximally 3 weeks. Subjects will complete period 2 on day 6, provided that all required assessments have been performed and there are no medical reasons for a prolonged follow-up. The study will be completed with an end-of-study visit (ESV), which will take place between 5 and 9 days after the last treatment period-defined assessment (or after early withdrawal).
All subjects:
Safety assessments will be performed throughout the study. An optional biobanking sample may be taken for potential exploratory, retrospective, gene polymorphism analysis. Roxadustat plasma, urine, and dialysate samples will be stored for potential exploratory metabolic profiling or exploratory biomarker analysis after the study.
Inclusion Criteria:
Inclusion criteria for all subjects:
Specific inclusion criteria for subjects with normal renal function:
Specific inclusion criteria for subjects with severely impaired renal function:
Specific inclusion criteria for subjects with ESRD on CAPD or APD:
Specific inclusion criteria for subjects with ESRD on HD or HDF:
Specific inclusion criteria for subjects with impaired renal function including severly impaired renal function and ESRD:
Exclusion Criteria:
Exclusion criteria for all subjects:
Specific exclusion criteria for subjects with normal renal function:
Subjects aged greater than or equal to 40 and \< 65:
Subjects aged greater than or equal to 65 and less than or equal to 75:
Subjects aged greater than or equal to 40 and \<65:
Subjects aged greater than or equal to 65 and less than or equal to 75:
Specific exclusion criteria for subjects with impaired renal function (including severely impaired renal function and ESRD):
Subject has an anticipated use of the following prohibited medication during the treatment and/or follow-up of the study:
Subject with any of the liver chemistry tests (AST, ALT and TBL) out of range as indicated below. In such a case the assessment may be repeated once [day -2].
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Normal renal function: eGFR is equal to or greater than 90 mL/min/1.73 m\^2. Single dose of roxadustat
Drug: Roxadustat
Severely impaired renal function: eGFR is less than 30 mL/min/1.73 m\^2. Single dose of roxadustat
Drug: Roxadustat
ESRD subjects on CAPD or APD need to be on the same mode of dialysis for at least 4 months. Single dose of roxadustat
Drug: Roxadustat
ESRD subjects on HD or HDF need to be on the same mode of dialysis for at least 4 months and should have dialysis sessions three times weekly. Single dose of roxadustat, in both treatment periods
Drug: Roxadustat
Oral
Also known as: FG-4592, ASP1517
Pharmacokinetics of Roxadustat in plasma: Cmax
Cmax: Maximum concentration
Time frame: Up to day 6
Pharmacokinetics of Roxadustat in plasma: Cmax,u
Cmax,u: Maximum concentration of unbound compound
Time frame: Up to day 6
Pharmacokinetics of Roxadustat in plasma: AUCinf
AUCinf: Area under the concentration-time curve from the time of dosing extrapolated to time infinity
Time frame: Up to day 6
Pharmacokinetics of Roxadustat in plasma: AUCinf,u
AUCinf,u: Area under the concentration-time curve from the time of dosing extrapolated to time infinity for unbound concentration
Time frame: Up to day 6
Pharmacokinetics of Roxadustat in plasma: AUClast
AUClast: Area under the concentration-time curve from the time of dosing to the last measurable concentration (Clast)
Time frame: Up to day 6
Pharmacokinetics of Roxadustat in plasma: AUClast,u
AUClast,u: Area under the concentration-time curve from the time of dosing to the last measurable concentration (Clast) for unbound concentration
Time frame: Up to day 6
Pharmacokinetics of Roxadustat in plasma: CL/F
CL/F: Apparent total systemic clearance after single or multiple extravascular dosing
Time frame: Up to day 6
Pharmacokinetics of Roxadustat in plasma: CLu/F
CLu/F: Apparent total systemic clearance of unbound compound after extravascular dosing
Time frame: Up to day 6
Pharmacokinetics of Roxadustat in plasma: fu
fu: Fraction of parent or metabolite available systemically unbound (= free fraction)
Time frame: Up to day 6
Pharmacokinetics of Roxadustat in plasma: tmax
tmax: Time of the maximum concentration
Time frame: Up to day 6
Pharmacokinetics of Roxadustat in plasma t1/2
t1/2: Terminal elimination half-life
Time frame: Up to day 6
Pharmacokinetics of Roxadustat in plasma: Vz/F
Vz/F: Apparent volume of distribution during the terminal elimination phase after single extravascular dosing
Time frame: Up to day 6
Pharmacokinetics of Roxadustat in plasma: Vz,u/F
Vz,u/F: Apparent volume of distribution during the terminal elimination phase of unbound compound after extravascular dosing
Time frame: Up to day 6
Pharmacokinetics of O-glucuronide-Roxadustat in plasma: Cmax
Time frame: Up to day 6
Pharmacokinetics of O-glucuronide-Roxadustat in plasma: AUCinf
Time frame: Up to day 6
Pharmacokinetics of O-glucuronide-Roxadustat in plasma: AUClast
Time frame: Up to day 6
Pharmacokinetics of O-glucuronide-Roxadustat in plasma: tlag
tlag: Time prior to the time corresponding to the first measurable (non-zero) concentration
Time frame: Up to day 6
Pharmacokinetics of O-glucuronide-Roxadustat in plasma: tmax
Time frame: Up to day 6
Pharmacokinetics of O-glucuronide-Roxadustat in plasma: t1/2
Time frame: Up to day 6
Pharmacokinetics of O-glucuronide-Roxadustat in plasma: MPR
MPR: Metabolite to parent ratio of AUC using AUC (corrected) for the metabolite (corrected by molecular weight ratio of parent to metabolite)
Time frame: Up to day 6
Pharmacokinetics of O-glucoside -Roxadustat in plasma: Cmax
Time frame: Up to day 6
Pharmacokinetics of O-glucoside-Roxadustat in plasma: AUCinf
Time frame: Up to day 6
Pharmacokinetics of O-glucoside-Roxadustat in plasma: AUClast
Time frame: Up to day 6
Pharmacokinetics of O-glucoside-Roxadustat in plasma: tlag
tlag: Time prior to the time corresponding to the first measurable (non-zero) concentration
Time frame: Up to day 6
Pharmacokinetics of O-glucoside-Roxadustat in plasma: tmax
Time frame: Up to day 6
Pharmacokinetics of O-glucoside-Roxadustat in plasma: t1/2
Time frame: Up to day 6
Pharmacokinetics of O-glucoside-Roxadustat in plasma: MPR
MPR: Metabolite to parent ratio of AUC using AUC(corrected) for the metabolite (corrected by molecular weight ratio of parent to metabolite)
Time frame: Up to day 6
Pharmacokinetics of sulfate of hydroxy-Roxadustat in plasma: Cmax
Time frame: Up to day 6
Pharmacokinetics of sulfate of hydroxy-Roxadustat in plasma: AUCinf
Time frame: Up to day 6
Pharmacokinetics of sulfate of hydroxy-Roxadustat in plasma: AUClast
Time frame: Up to day 6
Pharmacokinetics of sulfate of hydroxy-Roxadustat in plasma: tlag
tlag: Time prior to the time corresponding to the first measurable (non-zero) concentration
Time frame: Up to day 6
Pharmacokinetics of sulfate of hydroxy-Roxadustat in plasma: tmax
Time frame: Up to day 6
Pharmacokinetics of sulfate of hydroxy-Roxadustat in plasma: t1/2
Time frame: Up to day 6
Pharmacokinetics of sulfate of hydroxy-Roxadustat in plasma: MPR
Time frame: Up to day 6
Pharmacokinetics of Roxadustat in urine: CLR
CLR: Renal clearance
Time frame: Up to day 4
Pharmacokinetics of Roxadustat in urine: CLR,u
CLR,u: Renal clearance of unbound drug
Time frame: Up to day 4
Pharmacokinetics of Roxadustat in urine: Aeinf
Aeinf: Cumulative amount of compound excreted into urine from time of dosing extrapolated to time infinity
Time frame: Up to day 4
Pharmacokinetics of Roxadustat in urine: Aeinf%
Aeinf%: Percent of drug dose excreted into urine (Aeinf) from time of dosing extrapolated to time infinity
Time frame: Up to day 4
Pharmacokinetics of Roxadustat in urine: Aelast
Aelast: Cumulative amount of drug excreted into urine from time of dosing up to the collection time of the last measurable concentration
Time frame: Up to day 4
Pharmacokinetics of Roxadustat in urine: Aelast%
Aelast%: Percent of drug dose excreted into urine (Aelast) from time of dosing up to the collection time of the last measurable concentration
Time frame: Up to day 4
Pharmacokinetics of O-glucuronide-Roxadustat in urine: CLR
Time frame: Up to day 4
Pharmacokinetics of O-glucuronide-Roxadustat in urine: Aeinf
Time frame: Up to day 4
Pharmacokinetics of O-glucuronide-Roxadustat in urine: Aelast
Time frame: Up to day 4
Pharmacokinetics of O-glucuronide-Roxadustat in urine: MPR based on Aeinf
Time frame: Up to day 4
Pharmacokinetics of O-glucoside-Roxadustat in urine: CLR
Time frame: Up to day 4
Pharmacokinetics of O-glucoside-Roxadustat in urine: Aeinf
Time frame: Up to day 4
Pharmacokinetics of O-glucoside-Roxadustat in urine: Aelast
Time frame: Up to day 4
Pharmacokinetics of O-glucoside-Roxadustat in urine: MPR based on Aeinf
Time frame: Up to day 4
Pharmacokinetics of sulfate of hydroxy-Roxadustat in urine: CLR
Time frame: Up to day 4
Pharmacokinetics of sulfate of hydroxy-Roxadustat in urine: Aeinf
Time frame: Up to day 4
Pharmacokinetics of sulfate of hydroxy-Roxadustat in urine: Aelast
Time frame: Up to day 4
Pharmacokinetics of sulfate of hydroxy-Roxadustat in urine: MPR based on Aeinf
Time frame: Up to day 4
Pharmacokinetics of Roxadustat and its main metabolites in dialysate fluid: CLD
CLD: dialysis clearance. For ESRD subjects on CAPD or APD and for ESRD subjects on HD or HDF (treatment period 2 only)
Time frame: Up to day 2
Pharmacokinetics of Roxadustat in dialysate fluid: fD
fD: fraction of dose cleared by dialysis. For ESRD subjects on CAPD or APD and for ESRD subjects on HD or HDF (treatment period 2 only)
Time frame: Up to day 2
Pharmacokinetics of O-glucuronide-Roxadustat in urine: Aeinf%
Time frame: Up to day 4
Pharmacokinetics of O-glucoside-Roxadustat in urine: Aeinf%
Time frame: Up to day 4
Pharmacokinetics of sulfate of hydroxy-Roxadustat in urine: Aeinf%
Time frame: Up to day 4
Pharmacokinetics of Roxadustat in plasma: Effective t½ 48 hours
Effective t½ 48 hours: Effective half-life based on a dosing interval of 48 hours
Time frame: Up to day 6
Pharmacokinetics of Roxadustat in plasma: Effective t½ 56 hours
Effective t½ 56 hours: Effective half-life based on a dosing interval of 56 hours
Time frame: Up to day 6
Pharmacokinetics of O-glucuronide-Roxadustat in plasma: TER
TER: Total exposure ratio
Time frame: Up to day 6
Pharmacokinetics of O-glucoside-Roxadustat in plasma: TER
Time frame: Up to day 6
Pharmacokinetics of sulfate of hydroxy-Roxadustat in plasma: TER
Time frame: Up to day 6
Pharmacodynamics of Roxadustat assessed by measuring erythropoietin (EPO): Emax
Emax: Maximum effect
Time frame: Up to day 6
Pharmacodynamics of Roxadustat assessed by measuring erythropoietin (EPO): Emax-baseline
Emax-baseline: Maximum effect from baseline
Time frame: U to day 6
Pharmacodynamics of Roxadustat assessed by measuring erythropoietin (EPO): AUCE,last
AUCE,last: Area under the effect-time curve from the time of dosing to the last measurable effect
Time frame: Up to day 6
Pharmacodynamics of Roxadustat assessed by measuring erythropoietin (EPO): AUCE,last (baseline-corrected)
AUCE,last (baseline-corrected): Area under the effect-time curve from the time of dosing to the last measurable effect baseline corrected
Time frame: Up to day 6
Pharmacodynamics of Roxadustat assessed by measuring erythropoietin (EPO): tmax, EPO
tmax, EPO: Time to maximum EPO concentration
Time frame: Up to day 6
Safety assessed by nature, frequency, and severity of Adverse Events (AEs)
Time frame: Up to End of Study (EOS) (Up to day 15, period 2)
Number of participants with vital signs abnormalities and/or adverse events related to treatment
Vital signs include: blood pressure (systolic and diastolic) and pulse
Time frame: Up to EOS (Up to day 15, period 2)
Safety assessed by routine 12- lead electrocardiogram (ECG)
Routine 12-lead ECG measurements will be performed for the different renal function groups, as applicable, after the subject has been in a supine position for at least 5 minutes. All routine 12-lead ECG data will be listed by subject
Time frame: Up to EOS (Up to day 15, period 2)
Safety assessed by continuous heart rate (HR) measurement
Holter
Time frame: Up to day 2 (period 1)
Number of participants with laboratory value abnormalities and/or adverse events related to treatment
Safety laboratory tests include: hematology, biochemistry and urinalysis
Time frame: Up to EOS (Up to day 15, period 2)
Plan to share: Undecided — Studies conducted with product indications or formulations that remain in development are assessed after study completion to determine if Individual Participant Data can be shared. The plan to share Individual Participant Data is based on the status of product approval or termination of the compound, in addition to other study-specific criteria described on www.clinicalstudydatarequest.com under "Sponsor Specific Details for Astellas."
Ran from Dec 2016 to primary completion in Dec 2017, 11 months.
Of 213 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 11 months is above that.
Counting every sponsor, half of 231 studies reached it within 8 months; a quarter within 5 and three quarters within 16.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Roxadustat